en
Scientific article
Open access
English

Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic hcv infection: a meta-analysis

Published inJournal of Hepatology, vol. 72, no. 6, p. 1112-1121
Publication date2020
Abstract

Glecaprevir/pibrentasvir is approved for treating adults infected with HCV genotypes 1-6. In clinical trials, glecaprevir/pibrentasvir was associated with high rates of sustained virologic response at post-treatment week 12 (SVR12) and was well tolerated. A systematic review and meta-analysis of the real-world effectiveness and safety of glecaprevir/pibrentasvir were undertaken.

Citation (ISO format)
LAMPERTICO, Pietro et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic hcv infection: a meta-analysis. In: Journal of Hepatology, 2020, vol. 72, n° 6, p. 1112–1121. doi: 10.1016/j.jhep.2020.01.025
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal0168-8278
165views
98downloads

Technical informations

Creation10/16/2020 3:02:00 PM
First validation10/16/2020 3:02:00 PM
Update time03/15/2023 10:57:01 PM
Status update03/15/2023 10:57:00 PM
Last indexation02/12/2024 1:20:07 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack